A Multiple-Ascending-Dose Study of MK-1708 in Healthy Participants for Amyotrophic Lateral Sclerosis and Alzheimer’s Disease

The primary objective of this study is to evaluate the safety, tolerability, and pharmacokinetics of **MK-1708** in healthy participants. This investigation is crucial for understanding the potential therapeutic applications of MK-1708 in the context of **amyotrophic lateral sclerosis** and **Alzheimer’s disease**. By assessing these parameters, the study aims to establish a foundational understanding of the drug's profile, which is essential for future clinical development and potential treatment strategies for these neurodegenerative conditions.

The clinical trial involves participants diagnosed with **Amyotrophic lateral sclerosis** and Alzheimer's disease. The study population includes both male and female subjects, with an age range categorized under code "3," which typically represents adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria and lifestyle considerations such as diet, physical activity, or habits have not been detailed. The trial population was selected without any specified focus on vulnerable groups, ensuring a broad representation of the general adult population affected by these conditions.

The clinical trial is designed to evaluate the safety and efficacy of a new investigational product in participants diagnosed with **amyotrophic lateral sclerosis** and **Alzheimer's disease**. This study is a Phase 3, randomized, double-blind, controlled trial, which aims to provide robust data on the therapeutic potential of the investigational product. The trial is expected to commence recruitment on May 10, 2024, and is projected to conclude by September 16, 2024, marking the overall trial duration. Participants will be randomly assigned to either the investigational product group or a control group to ensure unbiased results.

The sequence of study visits begins with an inclusion visit, also known as the screening visit, where potential participants are assessed against the inclusion and exclusion criteria to determine eligibility. Following successful screening, participants will undergo a series of follow-up visits at predetermined intervals to monitor their health status, adherence to the study protocol, and any adverse events. These visits are crucial for collecting data on the primary and secondary endpoints of the trial. The end-of-study visit marks the final assessment of participants, where comprehensive evaluations are conducted to gather conclusive data on the investigational product's impact.

Participant involvement is expected to last for the entire duration of the trial, from the initial screening to the end-of-study visit. However, certain conditions may necessitate early termination from the study, such as the occurrence of significant adverse events, non-compliance with the study protocol, or withdrawal of consent by the participant. The trial is conducted under strict ethical guidelines and regulatory standards to ensure the safety and well-being of all participants throughout the study period.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these treatments can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be offered regarding these aspects of the clinical trial.

The clinical trial is in Phase 3 and is scheduled to have an estimated recruitment start date of May 10, 2024, with an estimated end date of September 16, 2024. The efficacy of the intervention will be assessed through specific parameters or endpoints, although these are not detailed in the provided data. The trial will follow a structured schedule for measuring, collecting, and analyzing these efficacy parameters, adhering to the standards expected in a Phase 3 trial. The methods and tools for efficacy assessment are not specified in the available information. The trial is categorized under trial category 1, with a trial category ID of 44870. The focus will be on evaluating the intervention's impact on the specified medical condition, ensuring that the data collected is robust and scientifically valid.